-
News | 2023.06.16
International: scientific partnerships and collaborations strengthened in 2022
The Institut Pasteur has been conducting its missions internationally since its creation in 1887. A policy of openness informs the Institut Pasteur’s strategic partnerships and scientific cooperation throughout the world, putting scientific excellence at the service of the health of populations. Also, as a cofounder of the Pasteur Network, the Institut Pasteur plays a key role in the co-...
-
News | 2023.06.12
Gut microbiota involved in depressive disorders
"A healthy mind... with a healthy microbiota." These words sum up a recent study demonstrating the close link between the composition of the gut microbiota and depressive disorders. In the same paper, the scientists also offered proof that direct communication between the gut microbiota and the brain requires the vagus nerve, paving the way for therapeutic solutions.
-
News | 2023.06.21
Malaria: parasite migration strategy revealed
Malaria is a disease transmitted by mosquitoes that are vectors of parasites in the genus Plasmodium. Scientists from the Institut Pasteur, in collaboration with specialized physicists in Brazil and Germany, have elucidated the search strategy used by parasites to reach the bloodstream.
-
News | 2023.06.28
From gene to patient, a decade of research to restore hearing
Scientists at the Hearing Institute, an Institut Pasteur Center, have established the full picture of therapeutic avenues for certain types of hearing impairments. They focused on so-called sensorineural deficiencies, caused by an anomaly in the inner ear or auditory nerve. Over the past 10 years, preclinical gene therapy studies have shown promising results. This research, aimed at restoring...
-
News | 2023.07.04
Extension of the Scope of the Exclusive Licence Granted by Institut Pasteur to Meletios Therapeutics for the Development of a New Class of Antivirals
The licensing agreement signed in 2022 between Institut Pasteur and Meletios Therapeutics, a French biotechnology company specialised in the research and development of next-generation antiviral treatments, concerns a cutting-edge technological platform for generating Defective Viral Genomes (DVGs) for the development of a new class of antivirals.
-
News | 2023.06.16
Strategic Plan: research advances in 2022
Five major themes were at the core of 2022 research advances: emerging infectious diseases, antimicrobial resistance, brain connectivity and neurodegenerative diseases, cancer, vaccinology and immunotherapy. They have honored Institut Pasteur's 2019-2023 strategic plan.
-
News | 2023.07.10
Enteric viruses with similar genomes in humans and great apes
A study conducted in Cameroon looked at enteric viruses in humans and some great ape species. These viruses share the same genomes. This "sharing" is thought to be a result of hunting, meat consumption and pillaging by great apes. The findings confirm the scale of pathogen transmission between humans and animals, which can represent a threat to human and animal health.
-
Document de presse | 2023.07.11
A global overview of antibiotic resistance determinants
To understand the main determinants behind worldwide antibiotic resistance dynamics, scientists from the Institut Pasteur, Inserm, Université de Versailles Saint-Quentin-en-Yvelines and Université Paris-Saclay developed a statistical model based on a large-scale spatial-temporal analysis. Using the ATLAS antimicrobial resistance surveillance database, the model revealed significant differences in...
-
Document de presse | 2023.07.12
Genetic variants implicated in autism detected in the general population
Scientists from the Institut Pasteur, the CNRS, the Institut universitaire de France, Université Paris Cité and the Paris Public Hospital Network (AP-HP) compared genetic data from 13,000 individuals with autism and nearly 200,000 individuals from the general population. While 4% of those with autism were found to carry strong genetic variations implicated in autism, the same variations were also...
-
Document de presse | 2023.07.20
HIV: 20 months' remission after a bone marrow transplant with no protective mutation – the Geneva patient
In February 2023, the IciStem consortium, which includes Asier Sáez-Cirión's team at the Institut Pasteur, published details in Nature Medicine of a third case of HIV remission after a bone marrow transplant, involving the Düsseldorf patient. A total of 5 individuals (the Berlin, London, Düsseldorf, New York and City of Hope patients) are now considered as having probably been cured of HIV...
